Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 3

1(16.7%)

Phase 1

1(16.7%)

6Total

Phase 2(4)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04755920Phase 2Recruiting

SGM-101 in Colorectal Brain Metastases.

Role: collaborator

NCT03659448Phase 3Recruiting

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

Role: lead

NCT05984810Phase 2Recruiting

NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101

Role: collaborator

NCT04737213Phase 2Unknown

SGM-101 in Colorectal Lung Metastases

Role: collaborator

NCT04642924Phase 2Unknown

SGM-101 in Locally Advanced and Recurrent Rectal Cancer

Role: collaborator

NCT02973672Phase 1Completed

Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas

Role: lead

All 6 trials loaded